Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

Cyclacel Pharmaceuticals, Inc. Form 4 March 13, 2007

March 13, 2	.007									
FORM	ЛΔ								PPROVAL	
-	UNITED	STATES					COMMISSIO	N OMB Number:	3235-0287	
Check tl if no lon subject t Section Form 4 o Form 5 obligatio may con <i>See</i> Insta 1(b).	ger STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF 6. SECURITIES r Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, ss Section 17(a) of the Public Utility Holding Company Act of 1935 or Section ans 20(b) of the Investment Company Act of 1940							Estimated burden hou response	urs per	
Print or Type	Responses)									
1. Name and A Legault Pie	Address of Reporting	Person <u>*</u>	2. Issuer Name and Ticker or Trading Symbol Cyclacel Pharmaceuticals, Inc. [CYCC]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(M				3. Date of Earliest Transaction (Month/Day/Year) 03/09/2007			X_ Director 10% Owner Officer (give title Other (specify below) below)			
				f Amendment, Date Original ed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
DEKKELE	I HEIGHIS, NJ	07922					Person			
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative Se	ecurities A	cquired, Disposed	of, or Beneficia	lly Owned	
.Title of Gecurity (Month/Day/Year) 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V		A) or (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securitie

Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)		r)	(Instr. 3 and 4	4)
				Code V	7 (A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Share
Options	\$ 7.8	03/09/2007		А	35,000	03/09/2007 <u>(1)</u>	03/09/2017	Common Stock	35,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Legault Pierre 200 CONNELL DRIVE, SUITE 1500 BERKELEY HEIGHTS, NJ 07922	Х					
Signatures						

м

/s/ Pierre Legault	03/13/2007
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Options shall vest ratably over a 48 month period.
- The Options were granted to Mr. Legault in exchange for his services rendered as a non-executive member of the Board of Directors and (2)Chair of the Audit Committee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.